Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1948 2
1949 2
1950 11
1951 10
1952 49
1953 106
1954 170
1955 334
1956 355
1957 367
1958 409
1959 380
1960 225
1961 217
1962 314
1963 602
1964 836
1965 665
1966 698
1967 826
1968 1011
1969 1097
1970 1150
1971 1155
1972 1211
1973 1307
1974 1326
1975 1242
1976 1237
1977 1196
1978 1161
1979 1281
1980 1281
1981 1201
1982 1309
1983 1446
1984 1557
1985 1585
1986 1518
1987 1412
1988 1387
1989 1334
1990 1362
1991 1296
1992 1306
1993 1228
1994 1169
1995 1206
1996 1193
1997 1222
1998 1260
1999 1234
2000 1284
2001 1327
2002 1379
2003 1364
2004 1451
2005 1479
2006 1715
2007 1766
2008 1706
2009 1780
2010 1924
2011 1996
2012 2074
2013 2085
2014 2039
2015 2115
2016 2044
2017 2130
2018 1999
2019 1992
2020 1989
2021 1878
2022 903
Text availability
Article attribute
Article type
Publication date

Search Results

82,445 results
Results by year
Filters applied: . Clear all
Page 1
Topical steroids.
Lee SS. Lee SS. Int J Dermatol. 1981 Dec;20(10):632-41. doi: 10.1111/j.1365-4362.1981.tb00391.x. Int J Dermatol. 1981. PMID: 7035382 Review. No abstract available.
Novel strategies for hydrocortisone replacement.
Debono M, Price JN, Ross RJ. Debono M, et al. Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):221-32. doi: 10.1016/j.beem.2008.09.010. Best Pract Res Clin Endocrinol Metab. 2009. PMID: 19500765 Review.
Current therapy with immediate-release hydrocortisone is the most commonly used regimen for replacement in patients with primary and secondary adrenal insufficiency. However, conventional hydrocortisone cannot provide the physiological rhythm of cortisol release. .. …
Current therapy with immediate-release hydrocortisone is the most commonly used regimen for replacement in patients with primary and …
Hydrocortisone aceponate.
Schmidt V, McEwan N, Nuttall T. Schmidt V, et al. J Small Anim Pract. 2009 Jun;50(6):317. doi: 10.1111/j.1748-5827.2009.00776.x. J Small Anim Pract. 2009. PMID: 19527428 No abstract available.
Therapies for adrenal insufficiency.
Oki K, Yamane K. Oki K, et al. Expert Opin Pharmacother. 2007 Jun;8(9):1283-91. doi: 10.1517/14656566.8.9.1283. Expert Opin Pharmacother. 2007. PMID: 17563263 Review.
The recommended protocol for maintenance therapy is 15-25 mg of hydrocortisone, divided into two or three separate doses. Patients with primary adrenal insufficiency generally receive mineralocorticoid replacement comprised of fludrocortisone 0.05-0.2 mg/day. ...When acute …
The recommended protocol for maintenance therapy is 15-25 mg of hydrocortisone, divided into two or three separate doses. Patients wi …
Immediate-release granule formulation of hydrocortisone, Alkindi®, for treatment of paediatric adrenal insufficiency (Infacort development programme).
Porter J, Withe M, Ross RJ. Porter J, et al. Expert Rev Endocrinol Metab. 2018 May;13(3):119-124. doi: 10.1080/17446651.2018.1455496. Epub 2018 Mar 26. Expert Rev Endocrinol Metab. 2018. PMID: 30058902 Free article. Review.
Treatment of paediatric patients with adrenal insufficiency is challenging due to the lack of appropriate glucocorticoid preparations for children, and the use of either pharmacy- or parent-compounded hydrocortisone tablets. Alkindi (hydrocortisone granules in capsu …
Treatment of paediatric patients with adrenal insufficiency is challenging due to the lack of appropriate glucocorticoid preparations for ch …
Evaluation of different hydrocortisone treatment strategies in transsphenoidal pituitary surgery.
Fridman-Bengtsson O, Höybye C, Porthén L, Stjärne P, Hulting AL, Sunnergren O. Fridman-Bengtsson O, et al. Acta Neurochir (Wien). 2019 Aug;161(8):1715-1721. doi: 10.1007/s00701-019-03885-6. Epub 2019 May 7. Acta Neurochir (Wien). 2019. PMID: 31065892 Free PMC article.
BACKGROUND: Hydrocortisone treatment in transsphenoidal pituitary surgery has been debated. ...LD hydrocortisone therapy seems to favor a better endogenous production in the early postoperative phase....
BACKGROUND: Hydrocortisone treatment in transsphenoidal pituitary surgery has been debated. ...LD hydrocortisone therapy seems …
[News for adrenal insufficiency].
Nunes ML, Tabarin A. Nunes ML, et al. Ann Endocrinol (Paris). 2008 Sep;69 Suppl 1:S44-52. doi: 10.1016/S0003-4266(08)73968-4. Ann Endocrinol (Paris). 2008. PMID: 18954859 Review. French.
This imperfect replacement may be responsible for adverse physical condition and impaired quality of life. Two formulations of delayed hydrocortisone tablets with different pharmacokinetics from usual hydrocortisone (DuoCort and Chronocort) are in development. ...
This imperfect replacement may be responsible for adverse physical condition and impaired quality of life. Two formulations of delayed hy
Cortisol in mood disorders.
Young AH. Young AH. Stress. 2004 Dec;7(4):205-8. doi: 10.1080/10253890500069189. Stress. 2004. PMID: 16019585 Review.
Obesity and cortisol status.
Salehi M, Ferenczi A, Zumoff B. Salehi M, et al. Horm Metab Res. 2005 Apr;37(4):193-7. doi: 10.1055/s-2005-861374. Horm Metab Res. 2005. PMID: 15952076 Review.
Controversies surrounding critical illness-related corticosteroid insufficiency in animals.
Creedon JM. Creedon JM. J Vet Emerg Crit Care (San Antonio). 2015 Jan-Feb;25(1):107-12. doi: 10.1111/vec.12270. Epub 2014 Dec 16. J Vet Emerg Crit Care (San Antonio). 2015. PMID: 25516097 Review.
The diagnosis in people is currently based on response to treatment with hydrocortisone. There is currently no consensus on appropriate diagnostic feature(s) in veterinary species. THERAPY: Low-dose hydrocortisone is the treatment of choice for patients with CIRCI. …
The diagnosis in people is currently based on response to treatment with hydrocortisone. There is currently no consensus on appropria …
82,445 results
You have reached the last available page of results. Please see the User Guide for more information.